ALK Gene Rearrangement clinical trials at University of California Health
1 research study open to eligible people
A Study of Chemotherapy with Experimental Crizotinib vs. Placebo For Non-Small Cell Lung Cancer After Surgery
“Can targeted chemotherapy with Crizotinib, stop the growth of tumor cells by blocking the a protein from working?”
open to eligible people ages 18 years and up
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
at UC Davis UCSD UCSF
Our lead scientists for ALK Gene Rearrangement research studies include Lyudmila A. Bazhenova.